관절 통증 주사 시장 : 규모, 점유율, 성장률 및 유형 및 용도별 세계 시장 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of joint pain injections Market

The global joint pain injections market was valued at USD 6.34 billion in 2025 and is projected to grow to USD 6.97 billion in 2026, reaching USD 15.67 billion by 2034, reflecting a CAGR of 10.70% during the forecast period. North America led the market in 2025 with a 45.52% share, driven by a high prevalence of osteoarthritis, advanced healthcare infrastructure, and favorable reimbursement policies. The U.S. joint pain injection market is projected to reach USD 5.49 billion by 2032, fueled by rising sports injuries and increasing awareness of joint disorders.

Joint pain injections are widely used for managing pain and inflammation in patients with musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. Corticosteroid injections are the first line of treatment, delivered directly to affected joints. The growing prevalence of musculoskeletal conditions and the focus of key players on developing novel therapies are key drivers of market growth.

During the COVID-19 pandemic, market growth declined due to reduced patient visits. However, post-pandemic recovery has been observed, supported by increasing awareness of musculoskeletal conditions and continuous introduction of innovative products.

Market Trends

The market is witnessing a shift toward minimally invasive procedures such as platelet-rich plasma (PRP) injections, hyaluronic acid (HA) injections, and plasma matrix therapy. These procedures provide rapid drug absorption, prolonged pain relief, and less discomfort, resulting in growing patient preference.

For instance, in August 2021, Bioventus invested in Trice Medical, Inc. to expand minimally invasive technologies for orthopedic procedures. Ongoing research, such as the phase 3 clinical trials conducted by Emory University (2022) using Mesenchymal Stem Cells (MSC) and Bone Marrow Concentrate (BMAC) for knee osteoarthritis, underscores the increasing adoption of innovative treatments.

Market Growth Factors

1. Rising Sports Injuries: Increasing ligament and muscle injuries are driving demand for joint pain injections. In 2022, the National Safety Council (U.S.) reported over 445,000 exercise equipment-related injuries, highlighting the growing patient pool for pain management therapies.

2. Awareness of Musculoskeletal Disorders: Government initiatives and awareness campaigns promote intra-articular injections, supporting market expansion. Higher per capita healthcare expenditure in developed countries also contributes to increased adoption.

3. Novel Product Launches: Companies are actively introducing advanced therapies to address unmet medical needs, enhancing market penetration.

Restraining Factors

High costs and limited access in emerging countries restrict adoption. For example, PRP injections in the U.S. cost around USD 500-2,000 per injection, requiring multiple doses for efficacy. Alternative treatments, such as physical therapy or oral medications, offer lower-cost solutions, limiting market growth in developing regions.

Market Segmentation

By Product:

• Hyaluronic Acid (HA) injections led with 66.38% share in 2026, driven by growing osteoarthritis prevalence and clinical awareness.
• Corticosteroid injections are widely used as the first line of treatment.
• Platelet-Rich Plasma (PRP) injections are expected to show the highest CAGR due to positive clinical outcomes in pain management.

By Joint Type:

• Knee injections dominated with 48.32% share in 2026, reflecting the high prevalence of knee osteoarthritis.
• Hip, hand & wrist, and others are projected to grow steadily as awareness and diagnosis increase.

By Distribution Channel:

• Retail pharmacies accounted for 85.31% share in 2026, driven by accessibility and affordability.
• Online pharmacies are gaining traction due to regulatory support and lower pricing.
• Hospital pharmacies continue to grow as hospital visits for orthopedic conditions increase.

Regional Insights

• North America: Market size USD 3.19 billion in 2026, driven by high osteoarthritis prevalence and government support.
• Asia Pacific: Fastest growth expected due to aging populations in Japan, China, and India. Market projections for 2026: Japan USD 0.53 billion, China USD 0.4 billion, India USD 0.1 billion.
• Europe: Moderate growth with government support and awareness initiatives. UK USD 0.33 billion, Germany USD 0.4 billion in 2026.
• Latin America & Middle East/Africa: Nominal growth due to rising musculoskeletal conditions and improving healthcare infrastructure.

Key Market Players

Major players include Bioventus, SEIKAGAKU CORPORATION, Zimmer Biomet, Anika Therapeutics, Sanofi, Pacira BioSciences, Teva Pharmaceutical, Ferring B.V., and Dr. Reddy's Laboratories. Companies focus on R&D, new product launches, and strategic partnerships to increase market share.

Industry Developments:

• Dec 2023: Bioventus partnered with Aetna Medicare Advantage to provide access to DUROLANE for knee osteoarthritis.
• Nov 2022: Anika Therapeutics' Cingal achieved positive Phase III results.
• March 2022: Sanofi collaborated with IGM Biosciences on immunology therapeutics.
• Jan 2022: SEIKAGAKU established SEIKAGAKU NORTH AMERICA CORPORATION for expansion.

Conclusion

The joint pain injections market is set to grow from USD 6.34 billion in 2025 to USD 15.67 billion by 2034, at a 10.70% CAGR, driven by increasing musculoskeletal disorders, sports injuries, awareness of minimally invasive procedures, and innovative product launches. North America remains the largest market, while Asia Pacific shows the fastest growth due to demographic shifts. Despite challenges like high costs and limited access in emerging markets, continuous technological innovation and expanding distribution channels are poised to propel market growth throughout the forecast period.

Segmentation By Product

• Corticosteroid Injections
• Hyaluronic Acid Injections
• Platelet Rich Plasma Injections
• Others

By Joint Type

• Knee
• Hip
• Hand & Wrist
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America (By Product, Joint Type, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Latin America (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Epidemiology Analysis of Osteoarthritis, Key Countries/ Region, 2025
• 4.2. Prevalence of Key Disorders, by Key Countries, 2025
• 4.3. Overview of Advancements in Therapies for Treatment of Osteoarthritis
• 4.4. New Product Launches, Key Players
• 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.6. Impact of COVID-19 on Joint Pain Injections Market

5. Global Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Corticosteroid Injections
  • 5.1.2. Hyaluronic Acid Injections
  • 5.1.3. Platelet Rich Plasma Injections
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Joint Type
  • 5.2.1. Knee
  • 5.2.2. Hip
  • 5.2.3. Hand & Wrist
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail Pharmacies
  • 5.3.3. Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Corticosteroid Injections
  • 6.1.2. Hyaluronic Acid Injections
  • 6.1.3. Platelet Rich Plasma Injections
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Joint Type
  • 6.2.1. Knee
  • 6.2.2. Hip
  • 6.2.3. Hand & Wrist
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail Pharmacies
  • 6.3.3. Online Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Corticosteroid Injections
  • 7.1.2. Hyaluronic Acid Injections
  • 7.1.3. Platelet Rich Plasma Injections
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Joint Type
  • 7.2.1. Knee
  • 7.2.2. Hip
  • 7.2.3. Hand & Wrist
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Online Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. Italy
  • 7.4.4. France
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of the Europe

8. Asia Pacific Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Corticosteroid Injections
  • 8.1.2. Hyaluronic Acid Injections
  • 8.1.3. Platelet Rich Plasma Injections
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Joint Type
  • 8.2.1. Knee
  • 8.2.2. Hip
  • 8.2.3. Hand & Wrist
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of the Europe

9. Latin America Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Corticosteroid Injections
  • 9.1.2. Hyaluronic Acid Injections
  • 9.1.3. Platelet Rich Plasma Injections
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Joint Type
  • 9.2.1. Knee
  • 9.2.2. Hip
  • 9.2.3. Hand & Wrist
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East and Africa Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Corticosteroid Injections
  • 10.1.2. Hyaluronic Acid Injections
  • 10.1.3. Platelet Rich Plasma Injections
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Joint Type
  • 10.2.1. Knee
  • 10.2.2. Hip
  • 10.2.3. Hand & Wrist
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Sanofi
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Teva Pharmaceutical Industries Ltd.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Anika Therapeutics, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Bioventus
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. SEIAGAKU CORPORATION
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Ferring B.V.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Pacira BioSciences, Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Dr. Reddy's Laboratories Ltd.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Zimmer Biomet
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Fidia Farmaceutici S.p.A.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)